PVLA
HEALTHCAREPalvella Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving PVLA Today?
No stock-specific AI insight has been generated for PVLA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$130.17
Fundamentals
Trading
PVLA News
20 articles- Ligand Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Ligand to Participate in May Investor ConferencesYahoo Finance·May 5, 2026
- Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant AngiokeratomasYahoo Finance·May 4, 2026
- Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026Yahoo Finance·Apr 30, 2026
- New Palvella Director Brings Rare Disease Insight To Low Valued StockYahoo Finance·Apr 26, 2026
- Inventiva Builds Up Leadership Team Ahead of Potential CommercializationYahoo Finance·Apr 22, 2026
- Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026Yahoo Finance·Apr 20, 2026
- Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of DirectorsYahoo Finance·Apr 13, 2026
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of SalesYahoo Finance·Apr 7, 2026
- Palvella’s Phase III Success And Fast Track Status Test Current ValuationYahoo Finance·Apr 2, 2026
- Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·Mar 31, 2026
- Palvella Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 31, 2026
- Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic MalformationsYahoo Finance·Mar 30, 2026
- Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual MeetingYahoo Finance·Mar 27, 2026
- Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) SignalThe Motley Fool·Mar 25, 2026
- Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 WinMotley Fool·Mar 24, 2026
- Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026Yahoo Finance·Mar 24, 2026
- Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient ServicesYahoo Finance·Mar 23, 2026
All 20 articles loaded
Price Data
52-Week Range
$130.17
Fundamentals
Trading
About Palvella Therapeutics Inc
Palvella Therapeutics, Inc. is a biotechnology company specializing in the development of groundbreaking therapies for rare genetic disorders, particularly those caused by specific gene mutations. Its lead investigational product aims to treat pachyonychia congenita, addressing significant unmet needs within this unique patient population. With a robust foundation in gene therapy, Palvella is committed to broadening its pipeline with innovative solutions designed to enhance patient quality of life. The company's strategic focus on research and development positions it to play a pivotal role in transforming the landscape of rare disease treatments, making it an appealing prospect for institutional investors.